Food Allergies

 
Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose
March 28, 2025

Your daily dose of the clinical news you may have missed.

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose
March 24, 2025

Your daily dose of the clinical news you may have missed.

Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose
March 17, 2025

Your daily dose of the clinical news you may have missed.

Dupilumab Cuts Food Allergy IgE Levels in Small Study: Daily Dose
March 14, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Neffy 1 mg Epinephrine Nasal Spray: Daily Dose
March 13, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar
March 10, 2025

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

FDA Approves Neffy 1 mg Epinephrine Nasal Spray, Only Needle-Free Treatment for Patients Weighing Less Than 30 kg
March 06, 2025

The FDA approval of neffy 1 mg follows the earlier approval of the 5 mg version in August 2024.

Omalizumab Efficacy and Safety Shown Superior to OIT in First Head-to-Head Multi-Food Allergy Trial
March 03, 2025

Safety findings from the phase 3 OUtMATCH trial were notable, including no adverse events for omlizumab vs 30.5% for OIT and epinephrine use for 0% vs 37.3%, respectively.

Epinephrine Nasal Spray Shows Rapid Symptom Relief in Pediatric Anaphylaxis Study
March 03, 2025

Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.

Dupilumab Reduces Specific IgE to Foods at 12 and 24 Months in Small Study
February 28, 2025

AAAAI 2025: Dupilumab was associated with a 56.9% reduction in IgE levels at 12 months and of 73.5% at 24 months, according to results presented at AAAAI 2025.